H.C. Wainwright analyst Joseph Pantginis says today's clinical updates from Iovance Biotherapeutics strengthen his investment thesis. The company's efforts to amend clinical programs and generate more powerful tumor-infiltrating lymphocytes therapies are each crucial for gaining market share in multiple clinical indications beyond melanoma, Pantginis tells investors in a research note titled "Important Chess Moves to Head Regulatory Agencies off at the Pass." He believes the advances Iovance is making on multiple fronts, including the clinical and commercial, should be viewed as important inflection points for the shares. The analyst keeps a Buy rating on Iovance Biotherapeutics with a $26 price target.